NHWK - Nighthawk Biosciences rises 21% on monkeypox vaccine R&D agreement

• Nighthawk Biosciences ( NYSE: NHWK ) is up 21% in premarket trading after stating in an SEC filing it has entered into an R&D agreement with Lytic Solutions to develop a monkeypox vaccine.
• The company said that the Lytic' platform that will be used to generate monkeypox construct sequences "has exhibited immunogenicity and vaccine success against other viral targets in non-human primates."
• Also, the approach "offers advantages over attenuated viruses and other commercially approved options for pox virus which carry serious safety concerns."
• Nighthawk will own all construct sequences conceived and developed.
• Seeking Alpha's Quant Rating views Nighthawk ( NHWK ) as a hold with high marks for valuation and profitability .

For further details see: